2026-2034年遺傳性性澱粉樣多發性神經病變治療藥物全球市場規模、佔有率、趨勢和成長分析報告

全球遺傳性性澱粉樣多發性神經病變) 治療市場預計將從 2025 年的 33.9 億美元成長至 2034 年的 71.6 億美元，2026 年至 2034 年的複合年成長率 (CAGR) 為 8.67%。該市場的成長主要得益於人們對罕見疾病日益成長的關注以及標靶治療的研發。遺傳性性澱粉樣多發性神經病變是一種影響神經系統並導致進行進行性損傷的遺傳性疾病。人們對罕見疾病的認知不斷提高以及基因研究的進步是推動市場成長的主要因素。製藥公司正大力投資研發，以開發針對疾病的有效治療方法，也促進了市場的擴張。

關鍵促進因素包括基因靜默藥物和肝臟移植技術等創新治療方法的開發。先進診斷工具的普及使得早期發現和治療成為可能，從而改善了患者的預後。監管支持和對孤兒藥的獎勵也促進了新治療方法的研發。此外，研究機構和製藥公司之間的合作正在加速新治療方法的推出。

遺傳性性澱粉樣多發性神經病變(FAP) 治療市場預計將取得重大進展。各公司可能會專注於個人化醫療和標靶治療，以提高療效並減少副作用。基因編輯和 RNA治療方法等先進技術的整合將進一步改善治療效果。隨著研究的不斷深入，市場預計將穩定成長，為患者提供更佳的解決方案。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和貢獻。

競爭格局：我們對主要市場參與企業的市場定位、產品系列、策略舉措和財務表現進行了詳細評估。這為了解競爭趨勢和主要參與者所採取的策略提供了寶貴的見解。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點，或針對特定細分市場的深入洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球遺傳性性澱粉樣多發性神經病變治療市場：依藥物類型分類

• 市場分析、洞察與預測
• 伊諾特森
• 塔法米迪斯
• 糕點師
• 其他

第5章：全球遺傳性性澱粉樣變性多發性神經病變治療市場：依疾病類型分類

• 市場分析、洞察與預測
• 遺傳性神經病變I 型 (FAP-I)
• 遺傳性性澱粉樣神經病變II 型 (FAP-II)
• 遺傳性性澱粉樣神經病變III 型 (FAP-III)
• 遺傳性神經病變IV 型 (FAP-IV)

第6章：全球遺傳性性澱粉樣多發性神經病變治療市場：依性別與類型分類

• 市場分析、洞察與預測
• 男性
• 女士

第7章 全球遺傳性性澱粉樣變性神經病變治療市場：依分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第8章：全球遺傳性性澱粉樣變性多發性神經病變治療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Pfizer Inc
  • Alnylam Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Corino Therapeutics Inc
  • Proclara Biosciences
  • Arcturus Therapeutics Inc
  • Eidos TherapeuticsInc
  • Prothena Corporation Plc
  • BridgeBio PharmaInc
  • SOM Biotech
  • Intellia TherapeuticsInc
  • Akcea TherapeuticsInc
  • Neurimmune Holding AG
  • Arcturus TherapeuticsInc
  • Proclara BiosciencesInc
  • Regeneron PharmaceuticalsInc

The global familial amyloid polyneuropathy therapeutics market size is expected to reach USD 7.16 Billion in 2034 from USD 3.39 Billion in 2025, growing at a CAGR of 8.67 during 2026-2034.This market is expanding due to the increasing focus on rare diseases and the development of targeted therapies. Familial amyloid polyneuropathy is a genetic disorder that affects the nervous system, leading to progressive disability. The growing awareness of rare diseases and advancements in genetic research are key factors driving market growth. Pharmaceutical companies are investing heavily in research and development to create effective treatments for this condition, which is contributing to market expansion.

Key drivers include the development of innovative therapies such as gene-silencing drugs and liver transplantation techniques. The increasing availability of advanced diagnostic tools is enabling early detection and treatment, improving patient outcomes. Regulatory support and incentives for orphan drugs are also encouraging the development of new therapies. Additionally, collaborations between research institutions and pharmaceutical companies are accelerating the introduction of novel treatments.

Looking ahead, the familial amyloid polyneuropathy therapeutics market is expected to witness significant advancements in treatment options. Companies are likely to focus on personalized medicine and targeted therapies to improve efficacy and reduce side effects. The integration of advanced technologies such as gene editing and RNA-based treatments will further enhance therapeutic outcomes. As research continues to progress, the market is anticipated to grow steadily and offer improved solutions for patients.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Type

• Inotersen
• Tafamidis
• Patisiran
• Others

By Disease Type

• Familial Amyloid Polyneuropathy-I (FAP-I)
• Familial Amyloid Polyneuropathy-II (FAP-II)
• Familial Amyloid Polyneuropathy-III (FAP-III)
• Familial Amyloid Polyneuropathy-IV (FAP-IV)

By Gender Type

• Male
• Female

By Distribution Channel

• Hospital Pharmacies
• Retail pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc., Eidos Therapeutics, Inc., Prothena Corporation plc, BridgeBio Pharma, Inc., SOM Biotech, Intellia Therapeutics, Inc., Akcea Therapeutics, Inc., Neurimmune Holding AG, Arcturus Therapeutics, Inc., Proclara Biosciences, Inc., Regeneron Pharmaceuticals, Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Inotersen Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tafamidis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Patisiran Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Familial Amyloid Polyneuropathy-I (FAP-I) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Familial Amyloid Polyneuropathy-II (FAP-II) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Familial Amyloid Polyneuropathy-III (FAP-III) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Familial Amyloid Polyneuropathy-IV (FAP-IV) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET: BY GENDER TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Gender Type
• 6.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Type
  • 8.2.2 By Disease Type
  • 8.2.3 By Gender Type
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Type
  • 8.3.2 By Disease Type
  • 8.3.3 By Gender Type
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Type
  • 8.4.2 By Disease Type
  • 8.4.3 By Gender Type
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Type
  • 8.5.2 By Disease Type
  • 8.5.3 By Gender Type
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Type
  • 8.6.2 By Disease Type
  • 8.6.3 By Gender Type
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer Inc
  • 10.2.2 Alnylam Pharmaceuticals Inc
  • 10.2.3 Ionis Pharmaceuticals Inc
  • 10.2.4 Corino Therapeutics Inc
  • 10.2.5 Proclara Biosciences
  • 10.2.6 Arcturus Therapeutics Inc
  • 10.2.7 Eidos TherapeuticsInc
  • 10.2.8 Prothena Corporation Plc
  • 10.2.9 BridgeBio PharmaInc
  • 10.2.10 SOM Biotech
  • 10.2.11 Intellia TherapeuticsInc
  • 10.2.12 Akcea TherapeuticsInc
  • 10.2.13 Neurimmune Holding AG
  • 10.2.14 Arcturus TherapeuticsInc
  • 10.2.15 Proclara BiosciencesInc
  • 10.2.16 Regeneron PharmaceuticalsInc